AbbVie could take BiTE of Tecvayli market share on Phase III MM win

If approved, etentamig would join the increasingly competitive multiple myeloma market, which has recently gained several targeted therapies. If approved, etentamig would join the increasingly competitive multiple myeloma market, which has seen the addition of several targeted therapies in recent years. AbbVie will share the findings of the CERVINO study with global regulators. Credit: Saiful52 / Shutterstock.com. AbbVie’s bispecific T-cell engager (BiTE) therapy, etentamig, has been shown to positively impact progression-free survival (PFS) in a Phase III trial in relapsed or refractory multiple myeloma (R/R MM) – positioning the therapy to take a portion of the market share held by…

Source: Clinical Trials Arena